Novanta's Q3 Net Income Plummets 44.5% Amid Rising Operating Costs

TL;DR

**Novanta's Q3 earnings are a red flag, showing declining profitability despite revenue growth, signaling deeper operational issues.**

AI Summary

Novanta Inc. reported a significant decrease in net income for the three months ended September 26, 2025, falling to $10.65 million from $19.19 million in the prior year, a 44.5% decline. For the nine months, net income dropped to $36.36 million from $47.62 million, a 23.6% decrease. Revenue saw a modest increase, reaching $247.84 million for the quarter, up from $244.41 million, and $722.25 million for the nine months, up from $711.19 million. Operating income decreased substantially, from $32.56 million to $21.85 million for the quarter, and from $83.88 million to $69.18 million for the nine months, primarily due to increased operating expenses, including a rise in restructuring, acquisition, and related costs from $2.50 million to $6.68 million for the quarter. Cash and cash equivalents decreased by $24.77 million to $89.22 million for the nine months ended September 26, 2025, compared to a $12.36 million decrease in the prior year, driven by lower net cash provided by operating activities and increased cash used in financing activities, including $20.21 million in common share repurchases. The company also increased its long-term debt to $445.66 million from $411.95 million since December 31, 2024.

Why It Matters

Novanta's sharp decline in net income, despite revenue growth, signals potential margin pressures and increased operational inefficiencies that investors should scrutinize. The significant increase in restructuring and acquisition costs, alongside a substantial reduction in cash from operations, suggests ongoing integration challenges or strategic shifts that could impact future profitability and cash flow. This performance contrasts with competitors who might be demonstrating stronger cost control, potentially eroding Novanta's competitive standing in the precision technology market. Employees might face uncertainty if restructuring continues, while customers could see impacts on product development or service if cost-cutting measures become more aggressive. The broader market may view this as a cautionary tale for companies undergoing rapid expansion or integration.

Risk Assessment

Risk Level: high — The company's net income decreased by 44.5% for the three months ended September 26, 2025, to $10.65 million from $19.19 million in the prior year, indicating significant profitability challenges. Additionally, cash provided by operating activities fell from $96.95 million in the nine months ended September 27, 2024, to $55.25 million in the current nine-month period, a 43% drop, severely impacting liquidity and financial flexibility.

Analyst Insight

Investors should consider reducing exposure to NOVTU given the substantial decline in net income and operating cash flow, coupled with increased debt. Await clearer signs of operational efficiency improvements and a reversal in profitability trends before considering new investments.

Financial Highlights

revenue

$722.25M

total Debt

$445.66M

net Income

$36.36M

cash Position

$89.22M

revenue Growth

+1.5%

Revenue Breakdown

Key Numbers

• $10.65M — Net Income (Q3 2025) (Decreased 44.5% from $19.19M in Q3 2024)
• $36.36M — Net Income (9 Months 2025) (Decreased 23.6% from $47.62M in 9 Months 2024)
• $247.84M — Revenue (Q3 2025) (Increased 1.4% from $244.41M in Q3 2024)
• $69.18M — Operating Income (9 Months 2025) (Decreased 17.5% from $83.88M in 9 Months 2024)
• $6.68M — Restructuring, Acquisition, and Related Costs (Q3 2025) (Increased 167.2% from $2.50M in Q3 2024)
• $55.25M — Net Cash Provided by Operating Activities (9 Months 2025) (Decreased 43% from $96.95M in 9 Months 2024)
• $89.22M — Cash and Cash Equivalents (Sept 26, 2025) (Decreased from $113.99M at Dec 31, 2024)
• $445.66M — Long-term Debt (Sept 26, 2025) (Increased from $411.95M at Dec 31, 2024)
• $20.21M — Repurchases of Common Shares (9 Months 2025) (Significant cash outflow in financing activities)

Key Players & Entities

• NOVANTA INC. (company) — registrant
• $10.65 million (dollar_amount) — net income for Q3 2025
• $19.19 million (dollar_amount) — net income for Q3 2024
• $36.36 million (dollar_amount) — net income for nine months 2025
• $47.62 million (dollar_amount) — net income for nine months 2024
• $247.84 million (dollar_amount) — revenue for Q3 2025
• $244.41 million (dollar_amount) — revenue for Q3 2024
• $6.68 million (dollar_amount) — restructuring, acquisition, and related costs for Q3 2025
• $2.50 million (dollar_amount) — restructuring, acquisition, and related costs for Q3 2024
• $55.25 million (dollar_amount) — net cash provided by operating activities for nine months 2025

FAQ

Risk Factors

• Increased Debt Levels [medium — financial]: The company's long-term debt increased to $445.66 million as of September 26, 2025, from $411.95 million at December 31, 2024. This increase, coupled with a significant decrease in operating cash flow, could strain financial flexibility and increase interest expense.
• Integration of Acquisitions [medium — operational]: The company acquired Keonn Technologies for $75.1 million. Successful integration of this and other potential future acquisitions is critical. Failure to integrate effectively could disrupt operations, dilute management focus, and prevent realization of expected synergies.
• Declining Profitability [high — financial]: Net income for Q3 2025 fell 44.5% to $10.65 million, and for the nine months, it decreased 23.6% to $36.36 million. This decline, driven by increased operating expenses including restructuring costs, raises concerns about margin pressure and future earnings potential.
• Increased Restructuring and Acquisition Costs [medium — operational]: Restructuring, acquisition, and related costs rose significantly to $6.68 million in Q3 2025 from $2.50 million in Q3 2024. These costs impact short-term profitability and indicate ongoing integration or restructuring activities that could pose operational challenges.
• Reduced Cash Flow from Operations [high — financial]: Net cash provided by operating activities decreased by 43% to $55.25 million for the nine months ended September 26, 2025, compared to $96.95 million in the prior year. This reduction, combined with share repurchases, led to a larger decrease in cash and cash equivalents.
• Dependence on Key Markets [medium — market]: The company supplies core technology solutions to medical and advanced industrial OEMs. Downturns or shifts in these specific end markets, such as precision manufacturing or precision medicine, could negatively impact demand for Novanta's products.

Industry Context

Novanta operates as a global supplier of core technology solutions for medical and advanced industrial OEMs. The company leverages expertise in precision medicine, robotics, automation, and advanced surgery. Key trends include the increasing demand for precision and performance in medical devices and industrial automation, driven by technological advancements and regulatory requirements.

Regulatory Implications

As a supplier to medical device manufacturers, Novanta's products may be subject to stringent quality and regulatory standards (e.g., FDA, MDR). Compliance with these regulations is critical for market access and maintaining customer trust. Changes in these regulations could impact product development and compliance costs.

What Investors Should Do

1. Monitor operating expense trends, particularly restructuring and acquisition costs, to assess their impact on profitability.
2. Evaluate the integration progress and performance of recent acquisitions, such as Keonn Technologies.
3. Analyze the drivers of the 43% decrease in operating cash flow and assess the sustainability of the current cash position and debt levels.
4. Observe revenue performance across different segments, noting the divergence between growth in Robotics and Automation/Advanced Surgery versus declines in Precision Manufacturing/Precision Medicine.

Key Dates

• 2025-04-08: Acquisition of Keonn Technologies, S.L. — Acquired 100% of Keonn, a manufacturer of RFID solutions, for $75.1 million. This expands Novanta's capabilities in automation and data capture.
• 2025-09-26: End of Q3 2025 reporting period — Reported a 44.5% decrease in net income for the quarter and a 23.6% decrease for the nine months, alongside increased debt and reduced operating cash flow.
• 2024-12-31: End of Fiscal Year 2024 — Reported total long-term debt of $411.95 million and provided a baseline for year-over-year comparisons.

Glossary

OEMs

Original Equipment Manufacturers. Companies that produce goods used in another company's end product. (Novanta supplies core technology solutions to medical and advanced industrial OEMs, making this a key customer segment.)

ASC Topic 606

Accounting Standards Codification Topic 606, 'Revenue from Contracts with Customers.' This standard governs how and when companies recognize revenue. (Novanta uses this standard to recognize revenue, generally upon shipment when control of goods transfers to the customer.)

Contract Liabilities

Represents obligations to transfer goods or services to a customer for which the company has received consideration. Includes deferred revenue and advance payments. (The balance of contract liabilities increased to $8.2 million as of September 26, 2025, indicating future revenue recognition.)

Contingent Consideration

Additional payments in a business acquisition that are dependent on the achievement of specified future events or targets. (Novanta has $4.5 million in estimated fair value of contingent consideration for the Keonn acquisition, with potential future payments up to $20 million.)

Monte Carlo simulation model

A computational technique that uses random sampling to model the probability of different outcomes in a process that cannot easily be predicted due to the intervention of random variables. (Used by Novanta to determine the fair value of contingent consideration in the Keonn acquisition.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Novanta Inc. has experienced a significant decline in net income, with Q3 2025 net income down 44.5% and nine-month net income down 23.6%. While revenue saw a modest increase of 1.4% for the quarter and 1.5% for the nine months, operating income decreased substantially due to a sharp rise in operating expenses, particularly restructuring, acquisition, and related costs which more than doubled. The company's financial position shows increased long-term debt and a larger decrease in cash and cash equivalents, driven by lower operating cash flow and financing activities like share repurchases.

Filing Documents

• novt-20250926.htm (10-Q) — 3637KB
• novt-ex31_1.htm (EX-31.1) — 14KB
• novt-ex31_2.htm (EX-31.2) — 15KB
• novt-ex32_1.htm (EX-32.1) — 7KB
• novt-ex32_2.htm (EX-32.2) — 7KB
• 0001193125-25-262774.txt ( ) — 16983KB
• novt-20250926.xsd (EX-101.SCH) — 1919KB
• novt-20250926_htm.xml (XML) — 4172KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION 1 ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 1 CONSOLIDATED BALANCE SHEETS (unaudited) 1 CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) 2 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) 3 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) 4 CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) 5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 6 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 30 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 41 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 41

— OTHER INFORMATION

PART II — OTHER INFORMATION 42 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 42 ITEM 1A.

RISK FACTORS

RISK FACTORS 42 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 43 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 43 ITEM 4. MINE SAFETY DISCLOSURES 43 ITEM 5. OTHER INFORMATION 43 ITEM 6. EXHIBITS 45

SIGNATURES

SIGNATURES 46 P ART I—FINANCIAL INFORMATION I tem 1. Financial Statements NOVANTA INC. C ONSOLIDATED BALANCE SHEETS (In thousands of U.S. dollars or shares) (Unaudited) September 26, December 31, 2025 2024 ASSETS Current assets Cash and cash equivalents $ 89,221 $ 113,989 Accounts receivable, net of allowance of $ 997 and $ 505 , respectively 170,563 151,026 Inventories 179,977 144,606 Prepaid income taxes and income taxes receivable 9,755 8,076 Prepaid expenses and other current assets 18,903 15,951 Total current assets 468,419 433,648 Property, plant and equipment, net 119,773 113,135 Operating lease assets 43,283 42,908 Deferred tax assets 27,088 22,887 Other assets 6,487 5,991 Intangible assets, net 193,248 185,844 Goodwill 647,513 584,098 Total assets $ 1,505,811 $ 1,388,511 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Current portion of long-term debt $ 5,685 $ 4,691 Accounts payable 100,210 76,890 Income taxes payable 4,007 16,000 Current portion of operating lease liabilities 10,165 9,879 Accrued expenses and other current liabilities 66,793 60,331 Total current liabilities 186,860 167,791 Long-term debt 445,658 411,949 Operating lease liabilities 40,407 40,548 Deferred tax liabilities 19,703 13,093 Income taxes payable 5,221 4,941 Other liabilities 6,486 4,491 Total liabilities 704,335 642,813 Commitments and contingencies (Note 15) Stockholders' equity: Preferred shares, no par value; Authorized shares: 7,000 ; No shares issued and outstanding — — Common shares, no par value; Authorized shares: unlimited ; Issued and outstanding: 35,846 and 35,938 , respectively 423,856 423,856 Additional paid-in capital 76,499 84,214 Retained earnings 303,907 267,549 Accumulated other comprehensive loss ( 2,786 ) ( 29,921 ) Total st

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 26, 2025 (Unaudited) 1. Basis of Presentation Novanta Inc. (collectively with its subsidiaries, referred to as "Novanta", the "Company", "we", "us", "our") is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers ("OEMs") a competitive advantage. Novanta combines deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to the customers' demanding applications. The accompanying unaudited interim consolidated financial statements have been prepared by the Company in United States ("U.S.") dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted. The interim consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods. The Company's unaudited interim consoli

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 26, 2025 (Unaudited) Standard Description Effective Date Effect on the Financial Statements or Other Significant Matters In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) -Improvements to Income Tax Disclosures." ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendments in this update affects financial statement disclosure only and, as a result, will have no impact on results of operations, cash flows or financial condition. In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." ASU 2024-03 improves financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at both interim and annual reporting periods. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 affects financial statement disclosure only and, as a result, will have no impact on results of operations, cash flows or financial condition. In September 2025, the FASB issued ASU 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)" ASU 2025-06 eliminates references to prescriptive software development stages and requires capitalization of internal-use software costs once management commits funding and project completion is probable, while also updating disclosure requirements to align with Property, P

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 26, 2025 (Unaudited) relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using the expected cost plus a margin. Shipping & Handling Costs The Company accounts for shipping and handling activities that occur after the transfer of control over the related goods as fulfillment activities rather than performance obligations. Shipping and handling fees charged to customers are recognized as revenue and the related costs are recorded in cost of revenue at the time of transfer of control. Warranties The standard warranty periods for the Company's products are typically 12 months to 36 months . The Company recognizes estimated liabilities associated with standard warranty periods for its products in accordance with the provisions of ASC 450, "Contingencies," as the Company has the ability to ascertain the likelihood of the liabilities and can reasonably estimate the amount of the liabilities. A provision for the estimated cost related to standard warranties is recorded as cost of revenue at the time revenue is recognized. The Company's estimate of the costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that the Company's experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liabilities are recorded at that time, with offsetting adjustments to cost of revenue. Practical Expedients and Exemptions The Company expenses incremental direct costs of obtaining a contract when incurred because the expected amortization period is typically one year or less. These costs are recorded within selling, general and administrative expenses in the consolidated statement of operations. The Company does not adjust the promised amount of consideration for the effects of

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 26, 2025 (Unaudited) Disaggregated Revenue See Note 16 for the Company's disaggregation of revenue by segment, geography and end market. The following table presents revenues disaggregated by the capabilities of the underlying products and technologies during the three and nine months ended September 26, 2025 and September 27, 2024, respectively (in thousands): Three Months Ended Nine Months Ended September 26, September 27, September 26, September 27, 2025 2024 2025 2024 Precision Manufacturing $ 45,180 $ 48,677 $ 133,596 $ 152,179 Robotics and Automation 80,136 80,027 236,558 210,643 Automation Enabling Technologies 125,316 128,704 370,154 362,822 Precision Medicine 60,848 63,088 174,021 195,399 Advanced Surgery 61,672 52,613 178,076 152,964 Medical Solutions 122,520 115,701 352,097 348,363 Total Revenue $ 247,836 $ 244,405 $ 722,251 $ 711,185 3. Business Combinations On April 8, 2025 , the Company acquired 100 % of the outstanding stock of Keonn Technologies, S.L. ("Keonn") pursuant to the terms of a Share Purchase Agreement. At the closing date, Keonn became a wholly-owned subsidiary of the Company. Keonn is a manufacturer of Radio-Frequency Identification ("RFID") solutions, based in Barcelona, Spain. The acquisition of Keonn has been accounted for as a business combination under ASC 805, Business Combinations ("ASC 805"). Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company's consolidated financial statements include results of operations for Keonn from the April 8, 2025 acquisition date. Consideration Transferred Pursuant to the Share Purchase Agreement, the Company acquired all outstanding equity of Keonn for estimated total purchase consideration of $ 75.1 million, which consist

View Full Filing

View this 10-Q filing on SEC EDGAR